GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of High Dose MHAA4549A in Healthy Volunteers
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02284607
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec, Canada
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 334
- Registration Number
- NCT02273973
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇭🇺Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
- Conditions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02271139
- Locations
- 🇺🇸
LAC USC Medical Center, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT02219724
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02162719
- Locations
- 🇺🇸
West Virginia University Hospitals Inc, Morgantown, West Virginia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02146313
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States
🇺🇸Hackensack Univ Med Ctr, Hackensack, New Jersey, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
- Conditions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02141087
A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02136524
A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02092792
- Locations
- 🇺🇸
Dana Farber Cancer Inst., Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02092831